Jiangsu Nhwa Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Jiangsu Nhwa Pharmaceutical wird ein jährliches Gewinn- und Umsatzwachstum von 17.8% bzw. 17.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.7% betragen.

Wichtige Informationen

17.8%

Wachstumsrate der Gewinne

17.8%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.0%
Wachstumsrate der Einnahmen	17.2%
Zukünftige Eigenkapitalrendite	17.7%
Analystenabdeckung	Good
Zuletzt aktualisiert	14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Oct 28

Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Apr 02

Recent updates

Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Oct 28

Is Now The Time To Put Jiangsu Nhwa Pharmaceutical (SZSE:002262) On Your Watchlist?

Oct 21

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has A Rock Solid Balance Sheet

Sep 20

The Market Doesn't Like What It Sees From Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Earnings Yet

Sep 04

Here's Why Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has Caught The Eye Of Investors

Jul 22

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Seems To Use Debt Rather Sparingly

Jun 16

Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Share Price Is Matching Sentiment Around Its Earnings

May 09

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Ticks All The Boxes When It Comes To Earnings Growth

Apr 18

Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Apr 02

Gewinn- und Umsatzwachstumsprognosen

SZSE:002262 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	8,086	1,727	N/A	1,480	7
12/31/2025	6,825	1,442	N/A	1,256	8
12/31/2024	5,789	1,210	N/A	1,072	4
9/30/2024	5,531	1,171	673	1,101	N/A
6/30/2024	5,405	1,121	752	1,184	N/A
3/31/2024	5,220	1,075	529	877	N/A
12/31/2023	5,042	1,037	634	1,008	N/A
9/30/2023	4,834	1,044	719	1,039	N/A
6/30/2023	4,698	998	560	911	N/A
3/31/2023	4,485	939	585	939	N/A
1/1/2023	4,299	901	533	861	N/A
9/30/2022	4,164	867	521	813	N/A
6/30/2022	4,072	834	537	768	N/A
3/31/2022	4,024	819	505	728	N/A
1/1/2022	3,936	798	495	701	N/A
9/30/2021	3,879	830	914	1,194	N/A
6/30/2021	3,744	787	880	1,171	N/A
3/31/2021	3,528	759	981	1,270	N/A
12/31/2020	3,361	729	980	1,248	N/A
9/30/2020	3,326	714	149	325	N/A
6/30/2020	3,534	694	257	424	N/A
3/31/2020	3,837	675	237	397	N/A
12/31/2019	4,149	663	146	306	N/A
9/30/2019	4,167	623	568	727	N/A
6/30/2019	4,090	585	371	518	N/A
3/31/2019	3,981	549	341	464	N/A
12/31/2018	3,858	525	234	405	N/A
9/30/2018	3,764	472	239	431	N/A
6/30/2018	3,581	447	N/A	468	N/A
3/31/2018	3,482	411	N/A	436	N/A
12/31/2017	3,394	395	N/A	452	N/A
9/30/2017	3,274	400	N/A	384	N/A
6/30/2017	3,181	347	N/A	365	N/A
3/31/2017	3,097	325	N/A	361	N/A
12/31/2016	3,018	310	N/A	277	N/A
9/30/2016	3,004	297	N/A	263	N/A
6/30/2016	2,937	284	N/A	230	N/A
3/31/2016	2,851	269	N/A	183	N/A
12/31/2015	2,767	258	N/A	204	N/A
9/30/2015	2,694	257	N/A	140	N/A
6/30/2015	2,628	246	N/A	141	N/A
3/31/2015	2,566	235	N/A	193	N/A
12/31/2014	2,501	223	N/A	160	N/A
9/30/2014	2,418	213	N/A	218	N/A
6/30/2014	2,375	201	N/A	233	N/A
3/31/2014	2,310	186	N/A	204	N/A
12/31/2013	2,236	176	N/A	194	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 002262Das prognostizierte Gewinnwachstum (17.8% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 002262Die Erträge des Unternehmens (17.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (26.2% pro Jahr).

Hohe Wachstumserträge: 002262Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 002262Die Einnahmen des Unternehmens (17.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (13.8% pro Jahr).

Hohe Wachstumseinnahmen: 002262Die Einnahmen des Unternehmens (17.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 002262Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.7%).

Jiangsu Nhwa Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Price target increased by 8.3% to CN¥31.30

Price target increased by 8.0% to CN¥27.29

Price target increased to CN¥22.28

Price target increased to CN¥20.24

Recent updates

Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Is Now The Time To Put Jiangsu Nhwa Pharmaceutical (SZSE:002262) On Your Watchlist?

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Q3, 2024 Results on Oct 26, 2024

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has A Rock Solid Balance Sheet

The Market Doesn't Like What It Sees From Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Earnings Yet

Now 20% undervalued

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Here's Why Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has Caught The Eye Of Investors

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2024 Results on Jul 31, 2024

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Seems To Use Debt Rather Sparingly

Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Share Price Is Matching Sentiment Around Its Earnings

Jiangsu Nhwa Pharmaceutical (SZSE:002262) Ticks All The Boxes When It Comes To Earnings Growth

Now 21% overvalued

Earnings Update: Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS misses analyst expectations

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 24, 2024

Investor sentiment deteriorates as stock falls 17%

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2023 Results on Mar 30, 2024

Price target increased by 8.3% to CN¥31.30

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2023 Results on Jul 31, 2023

Jiangsu Nhwa Pharmaceutical Co., Ltd. Receives Formal Approval from the National Medical Products Administration for OLINVYK

Price target increased by 8.0% to CN¥27.29

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Price target increased to CN¥22.28

Price target increased to CN¥20.24

Third quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yulan as Independent Directors

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Insufficient new directors

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Price target decreased to CN¥16.18

Jiangsu Nhwa Pharmaceutical Co., Ltd Proposes Cash Dividend for 2021

Price target increased to CN¥18.01

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.21 in 2Q 2020)

Jiangsu Nhwa Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 02 June 2021

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 1Q 2020)

Revenue beats expectations, earnings disappoint

New 90-day low: CN¥13.53

Full year 2020 earnings released: EPS CN¥0.72 (vs CN¥0.66 in FY 2019)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥14.10

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2020 Results on Mar 12, 2021

New 90-day low: CN¥15.46

New 90-day high: CN¥18.50

Third quarter earnings released

Third-quarter earnings released: Earnings beat expectations, revenue disappoints

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥15.34

New 90-day low - CN¥15.61

New 90-day high - CN¥18.57

Price target raised to CN¥16.28

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2020 Results on Jul 31, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken